The Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review

Schandra Purnamawati, Niken Indrastuti, Retno Danarti, Tatan Saefudin, Schandra Purnamawati, Niken Indrastuti, Retno Danarti, Tatan Saefudin

Abstract

Moisturizer is a major component of basic daily skin care, particularly in presence of epidermal barrier alteration and reduced epidermal water content. It is an important part of a dermatologist's strategy to maintain skin health as well as treating various dermatoses which co-exist with skin dryness and are linked to impaired skin barrier function, such as in atopic disorders as well as other types of dermatitis. Mastering the knowledge regarding mechanism of action, application, dosage, adverse effects as well as specific clinical usage of moisturizers is a must for a dermatologist in order to support their use, particularly for evidence-based, therapeutic purposes. This review discusses the use of moisturizer both for skin health maintenance as well as a definitive or adjuvant therapy for many kinds of dermatitis.

Keywords: Atopic dermatitis; Contact dermatitis; Moisturizers; Nummular dermatitis; Seborrheic dermatitis.

© 2017 Marshfield Clinic.

References

    1. Lodén M. The clinical benefit of moisturizers. J Eur Acad Dermatol Venereol. 2005;19(6):672–688, quiz 686–687.
    1. Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4(11):771–788.
    1. Ginsburg IH. The psychosocial impact of skin disease. An overview. Dermatol Clin. 1996;14(3):473–484.
    1. Baumann L. Moisturizing Agents. In: Baumann L, editor. Cosmetic Dermatology- Principles and Practices. 1st ed. New York: Tata McGraw Hill; 2002;93–99.
    1. Diana Draelos Z. Therapeutic moisturizers. Dermatol Clin. 2000;18(4):597–607.
    1. Lodén M. Effect of moisturizers on epidermal barrier function. Clin Dermatol. 2012;30(3):286–296.
    1. Marks R. Emollients. London: Martin Dunitz Ltd; 2002.
    1. Nolan K, Marmur E. Moisturizers: Reality and the skin benefits. Dermatol Ther. 2012;25(3):229–233.
    1. Kraft JN, Lynde CW. Moisturizers: what they are and a practical approach to product selection. Skin Therapy Lett. 2005;10(5):1–8.
    1. Rawlings AV, Canestrari DA, Dobkowski B. Moisturizer technology versus clinical performance. Dermatol Ther. 2004;17(s1)(Suppl 1):49–56.
    1. Johnson AW. Cosmeceuticals: Function and the skin barrier. In: Draelos ZD, editor. Procedures in cosmetic dermatology series: cosmeceuticals. 1st ed. Philadelphia: Elsevier; 2005; 97–102.
    1. Lynde CW. Moisturizers: what they are and how they work. Skin Therapy Lett. 2001;6(13):3–5.
    1. Madison KC. Barrier function of the skin: la raison dêtre of the epidermis. J Invest Dermatol. 2003;121(2):231–241.
    1. Jemec GB, Na R. Hydration and plasticity following long-term use of a moisturizer: a single-blind study. Acta Derm Venereol. 2002;l 82(5):322–324.
    1. Mao-Qiang M, Brown BE, Wu-Pong S, Feingold KR, Elias PM. Exogenous nonphysiologic vs physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol. 1995;131(7):809–816.
    1. Ghadially R, Halkier-Sorensen L, Elias PM. Effects of petrolatum on stratum corneum structure and function. J Am Acad Dermatol. 1992;26(3):387–396.
    1. Diana Draelos Z. Therapeutic moisturizers. Dermatol Clin. 2000;18(4):597–607.
    1. Summers RS, Summers B, Chandar P, Feinberg C, Gurskey R, Rawlings AV. The effect of lipids with and without humectant on skin xerosis. J Soc Cosmet Chem. 1996;47:27–39.
    1. Rawlings AV, Davies A, Carlomusto M, et al. Effect of lactic acid isomers on keratinocyte ceramide synthesis, stratum corneum lipid levels and stratum corneum barrier function. Arch Dermatol Res. 1996;288(7):383–390.
    1. Marks R. Xerosis. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I, editors. Treatment of skin disease: comprehensive therapeutic strategies. 1st ed. New York: Mosby; 2002;665–667.
    1. Bikowski J. The use of therapeutic moisturizers in various dermatologic disorders. Cutis. 2001;68 (Suppl):(5)3–11.
    1. Ivens UI, Steinkjer B, Serup J, Tetens V. Ointment is evenly spread on the skin, in contrast to creams and solutions. Br J Dermatol. 2001;145(2):264–267.
    1. Ashida Y, Ogo M, Denda M. Epidermal interleukin-1alpha generation is amplified at low humidity: implications for the pathogenesis of inflammatory dermatoses. Br J Dermatol. 2001;144(2):238–243.
    1. Morris-Jones R, Robertson SJ, Ross JS, White IR, McFadden JP, Rycroft RJG. Dermatitis caused by physical irritants. Br J Dermatol. 2002;147(2):270–275.
    1. Garg A, Chren MM, Sands LP, et al. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol. 2001;137(1):53–59.
    1. Kabashima K. New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci. 2013;70(1):3–11.
    1. Simpson E, Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. J Drugs Dermatol. 2011;10(7):744–749.
    1. Moncrieff G, Cork M, Lawton S, Kokiet S, Daly C, Clark C. Use of emollients in dry-skin conditions: consensus statement. Clin Exp Dermatol. 2013;38(3):231–238, quiz 238.
    1. Rubel D, Thirumoorthy T, Soebaryo RW, et al. Asia-Pacific Consensus Group for Atopic Dermatitis. Consensus guidelines for the management of atopic dermatitis: An Asia-Pacific perspective. J Dermatol. 2013;40(3):160–171.
    1. Danby SG, AlEnezi T, Sultan A, et al. Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care. Pediatr Dermatol. 2013;30(1):42–50.
    1. Darmstadt G, Saha S, Ahmed A, et al. Effect of topical treatment with skin barrier-enhancing emollients on nosocomial infections in preterm infants in Bangladesh: a randomised controlled trial. Lancet. 2005;365(9464):1039–1045.
    1. Matsumoto K, Mizukoshi K, Oyobikawa M, Ohshima H, Sakai Y, Tagami H. Objective evaluation of the efficacy of daily topical applications of cosmetics bases using the hairless mouse model of atopic dermatitis. Skin Res Technol. 2005;11(3):209–217.
    1. Choi MJ, Maibach HI. Role of ceramides in barrier function of healthy and diseased skin. Am J Clin Dermatol. 2005;6(4):215–223.
    1. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47(2):198–208.
    1. Lohani A, Verma A, Joshi H, Yadav N, Karki N. Nanotechnology-Based Cosmeceuticals. ISRN Dermatology; 2014: Article ID 843687.
    1. Varothai S, Nitayavardhana S, Kulthanan K. Moisturizers for patients with atopic dermatitis. Asian Pac J Allergy Immunol. 2013;31(2):91–98.
    1. Paediatric Dermatology Subspecialty Core Group of the Philippine Dermatological Society. A guide to understanding moisturizers in atopic dermatitis. Quezon (PH): Philippine Dermatological Society; 2014.
    1. Feily A, Namazi MR. Aloe vera in dermatology: a brief review. G Ital Dermatol Venereol. 2009;144(1):85–91.
    1. Bedi MK, Shenefelt PD. Herbal therapy in dermatology. Arch Dermatol. 2002;138(2):232–242.
    1. DalBelo SE, Rigo Gaspar L, Berardo Gonçalves Maia Campos PM. Moisturizing effect of cosmetic formulations containing Aloe vera extract in different concentrations assessed by skin bioengineering techniques. Skin Res Technol. 2006;12(4):241–246.
    1. Shenefelt PD. Herbal Treatment for Dermatologic Disorders. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. Florida: Boca Raton; 2011.
    1. Arenberger P, Arenbergerová M, Drozenová H, Hladíková M, Holcová S. Effect of topical heparin and levomenol on atopic dermatitis: a randomized four-arm, placebo-controlled, double-blind clinical study. J Eur Acad Dermatol Venereol. 2011;25(6):688–694.
    1. Goreja WG. Shea Butter: The Nourishing Properties of Africa’s Best-Kept Natural Beauty Secret. New York: Amazing Herb Press; 2004.
    1. Akihisa T, Kojima N, Kikuchi T, et al. Anti-inflammatory and chemopreventive effects of triterpene cinnamates and acetates from shea fat. J Oleo Sci. 2010;59(6):273–280.
    1. Kim ME, Kim HK, Kim DH, Yoon JH, Lee JS. 18β-Glycyrrhetinic acid from licorice root impairs dendritic cells maturation and Th1 immune responses. Immunopharmacol Immunotoxicol. 2013;35(3):329–335.
    1. Kolbe L, Immeyer J, Batzer J, et al. Anti-inflammatory efficacy of Licochalcone A: correlation of clinical potency and in vitro effects. Arch Dermatol Res. 2006;298(1):23–30.
    1. Furusawa J, Funakoshi-Tago M, Mashino T, et al. Glycyrrhiza inflata-derived chalcones, Licochalcone A, Licochalcone B and Licochalcone D, inhibit phosphorylation of NF-κB p65 in LPS signaling pathway. Int Immunopharmacol. 2009;9(4):499–507.
    1. Udompataikul M, Srisatwaja W. Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study. J Eur Acad Dermatol Venereol. 2011;25(6):660–665.
    1. Schweiger D, Baufeld C, Drescher P, et al. Efficacy of a new tonic containing urea, lactate, polidocanol, and glycyrrhiza inflata root extract in the treatment of a dry, itchy, and subclinically inflamed scalp. Skin Pharmacol Physiol. 2013;26(2):108–118.
    1. Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol. 2000;143(3):524–531.
    1. Mohammed D, Crowther JM, Matts PJ, Hadgraft J, Lane ME. Influence of niacinamide containing formulations on the molecular and biophysical properties of the stratum corneum. Int J Pharm. 2013;441(1–2):192–201.
    1. Soma Y, Kashima M, Imaizumi A, Takahama H, Kawakami T, Mizoguchi M. Moisturizing effects of topical nicotinamide on atopic dry skin. Int J Dermatol. 2005;44(3):197–202.
    1. Christman JC, Fix DK, Lucus SC, et al. Two randomized, controlled, comparative studies of the stratum corneum integrity benefits of two cosmetic niacinamide/glycerin body moisturizers vs. conventional body moisturizers. J Drugs Dermatol. 2012;11(1):22–29.
    1. Kircik L. A nonsteroidal lamellar matrix cream containing palmitoylethanolamide for the treatment of atopic dermatitis. J Drugs Dermatol. 2010;9(4):334–338.
    1. D’Agostino G, La Rana G, Russo R, et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-κB nuclear signalling in dorsal root ganglia. Eur J Pharmacol. 2009;613(1–3):54–59.
    1. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008;22(1):73–82.
    1. Poiraud C, Quereux G, Knol AC, et al. Human β-defensin-2 and psoriasin, two new innate immunity targets of zinc gluconate. Eur J Dermatol. 2012;22(5):634–639.
    1. Poiraud C, Quereux G, Knol AC, Allix R, Khammari A, Dreno B. Zinc gluconate is an agonist of peroxisome proliferator-activated receptor-α in the epidermis. Exp Dermatol. 2012;21(5):347–351.
    1. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010;26(3):633–640.
    1. Boguniewicz M, Zeichner JA, Eichenfield LF, et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. J Pediatr. 2008;152(6):854–859.
    1. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132.
    1. Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. Dermatol Clin. 2003;21(3):401–412.
    1. Borda LJ, Wikramanayake TC. Seborrheic Dermatitis and Dandruff: A Comprehensive Review. J Clin Investig Dermatol. 2015;3(2):10.
    1. Turner GA, Hoptroff M, Harding CR. Stratum corneum dysfunction in dandruff. Int J Cosmet Sci. 2012;34(4):298–306.
    1. Schwartz JR, Cardin CW, Dawson TL. Seborrheic dermatitis and dandruff. In: Baran R, Maibach HI, editor. Textbook of Cosmetic dermatology. London: Martin Dunitz, Ltd; 2010: 230–241.
    1. Harding CR, Moore AE, Rogers SJ, Meldrum H, Scott AE, McGlone FP. Dandruff: a condition characterized by decreased levels of intercellular lipids in scalp stratum corneum and impaired barrier function. Arch Dermatol Res. 2002;294(5):221–230.
    1. Kerr K, Darcy T, Henry J, et al. Epidermal changes associated with symptomatic resolution of dandruff: biomarkers of scalp health. Int J Dermatol. 2011;50(1):102–113.
    1. Naldi L, Rebora A. Clinical practice: seborrheic dermatitis. N Engl J Med. 2009;360(4):387–396.
    1. Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthet Dermatol. 2011;4(5):32–38.
    1. Nalamothu V, OLeary AL, Kandavilli S, Fraser J, Pandya V. Evaluation of a nonsteroidal topical cream in a guinea pig model of Malassezia furfur infection. Clin Dermatol. 2009;27(Suppl):(6)S41–S43.
    1. Kircik L. An open-label, single-center pilot study to determine the antifungal activity of a new nonsteroidal cream (Promiseb Topical Cream) after 7 days of use in healthy volunteers. Clin Dermatol. 2009;27 (Suppl):(6)S44–S47.
    1. Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol. 2009;27 (Suppl):(6)S48–S53.
    1. Usatine RP. Contact dermatitis. In: Usatine RP, Smith M, Mayeaux EJ, Jr, editor. Color Atlas of Family Medicine. New York: McGraw-Hill; 2009.
    1. American Academy of Allergy. Asthma and Immunology; American College of Allergy, Asthma and Immunology. Contact dermatitis: a practice parameter. Ann Allergy Asthma Immunol. 2006;97(3 Suppl 2):S1–S38.
    1. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267–284.
    1. Nicholson PJ. Evidence-based guidelines: occupational contact dermatitis and urticaria. Occup Med (Chic Ill). 2010;60(7):502–504.
    1. Coenraads PJ. Hand Eczema. N Engl J Med. 2012;367(19):1829–1837.
    1. Kucharekova M, van de Kerkhof PCM, van der Valk PGM. A randomized comparison of an emollient containing skin-related lipids with a petrolatum-based emollient as adjunct in the treatment of chronic hand dermatitis. Contact Dermat. 2003;48(6):293–299.
    1. Gutman AB, Kligman AM, Sciacca J, James WD. Soak and Smear: a standard technique revisited. Arch Dermatol. 2005;141(12):1556–1559.
    1. Lodén M, Andersson AC. Effect of topically applied lipids on surfactant-irritated skin. Br J Dermatol. 1996;134(2):215–220.
    1. Kelly GS. Squalene and its potential clinical uses. Altern Med Rev. 1999;4(1):29–36.
    1. Wołosik K, Knaś M, Zalewska A, Niczyporuk M, Przystupa AW. The importance and perspective of plant-based squalene in cosmetology. J Cosmet Sci. 2013;64(1):59–66.
    1. Aoyama H, Tanaka M, Hara M, Tabata N, Tagami H. Nummular eczema: An addition of senile xerosis and unique cutaneous reactivities to environmental aeroallergens. Dermatology. 1999; 199: 135–139.
    1. Ozkaya E. Adult-onset atopic dermatitis. J Am Acad Dermatol. 2005; 52: 579–582.
    1. Jiamton S, Tangjaturonrusamee C, Kulthanan K. Clinical features and aggravating factors in nummular eczema in Thais. Asian Pac J Allergy Immunol. 2013;31(1):36–42.
    1. Bendl BJ. Nummular eczema of statis origin. The backbone of a morphologic pattern of diverse etiology. Int J Dermatol. 1979;18(2):129–135.
    1. Shen Y, Pielop J, Hsu S. Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection. Arch Dermatol. 2005; 141: 102–103.
    1. Flendrie M, Vissers WHPM, Creemers MCW, de Jong EMGJ, van de Kerkhof PCM, van Riel PLCM. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666–R676.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit